Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

BACKGROUND: Laquinimod is an oral immunomodulator in clinical development to treat relapsing-remitting multiple sclerosis (RRMS). Laquinimod is in clinical development for the treatment of multiple sclerosis and Huntington Disease (HD). The objective of this study is to assess the safety, tolerabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Tumani, Hayrettin, Sehr, Tony, Thomas, Katja, Paul, Friedemann, Richter, Nils, Samara, Emil, Spiegelstein, Ofer, Sorani, Ella, Bar-Ilan, Oren, Mimrod, Dorit, Hayardeny, Liat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577769/
https://www.ncbi.nlm.nih.gov/pubmed/28859672
http://dx.doi.org/10.1186/s12974-017-0945-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577769/
https://www.ncbi.nlm.nih.gov/pubmed/28859672
http://dx.doi.org/10.1186/s12974-017-0945-z

Ejemplares similares